{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:50:23Z","timestamp":1784202623764,"version":"3.55.0"},"reference-count":99,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":769,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Alcohol Clin Exp Res"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1111\/acer.12197","type":"journal-article","created":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T22:31:26Z","timestamp":1374705086000},"page":"2128-2137","source":"Crossref","is-referenced-by-count":54,"title":["The Placebo Effect in Clinical Trials for Alcohol Dependence: An Exploratory Analysis of 51 Naltrexone and Acamprosate Studies"],"prefix":"10.1111","volume":"37","author":[{"given":"Raye Z.","family":"Litten","sequence":"first","affiliation":[{"name":"Division of Treatment and Recovery Research ; National Institute on Alcohol Abuse and Alcoholism; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Jen P.","family":"Castle","sequence":"additional","affiliation":[{"name":"CSR, Incorporated ; Arlington Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Falk","sequence":"additional","affiliation":[{"name":"Division of Treatment and Recovery Research ; National Institute on Alcohol Abuse and Alcoholism; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Ryan","sequence":"additional","affiliation":[{"name":"Division of Treatment and Recovery Research ; National Institute on Alcohol Abuse and Alcoholism; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Fertig","sequence":"additional","affiliation":[{"name":"Division of Treatment and Recovery Research ; National Institute on Alcohol Abuse and Alcoholism; Bethesda Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiung M.","family":"Chen","sequence":"additional","affiliation":[{"name":"CSR, Incorporated ; Arlington Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiao-ye","family":"Yi","sequence":"additional","affiliation":[{"name":"CSR, Incorporated ; Arlington Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,7,24]]},"reference":[{"key":"10.1111\/acer.12197-BIB0001|acer12197-cit-0001","first-page":"85","article-title":"A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence","volume":"5","author":"Ahmadi","year":"2002","journal-title":"German J Psychiatry"},{"key":"10.1111\/acer.12197-BIB0002|acer12197-cit-0002","unstructured":"American Psychiatric Association 1980 Diagnotic and Statistical Manual of Mental Disorders 3rd ed American Psychiatric Association Washington, DC"},{"key":"10.1111\/acer.12197-BIB0003|acer12197-cit-0003","unstructured":"American Psychiatric Association 1987 Diagnotic and Statistical Manual of Mental Disorders 3rd ed. revised American Psychiatric Association Washington, DC"},{"key":"10.1111\/acer.12197-BIB0004|acer12197-cit-0004","unstructured":"American Psychiatric Association 1994 Diagnotic and Statistical Manual of Mental Disorders 4th ed American Psychiatric Association Washington DC"},{"key":"10.1111\/acer.12197-BIB0005|acer12197-cit-0005","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/01.jcp.0000172071.81258.04","article-title":"Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence","volume":"25","author":"Anton","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/acer.12197-BIB0006|acer12197-cit-0006","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1176\/ajp.156.11.1758","article-title":"Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial","volume":"156","author":"Anton","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1111\/acer.12197-BIB0007|acer12197-cit-0007","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1176\/appi.ajp.2011.10101436","article-title":"Gabapentin combined with naltrexone for the treatment of alcohol dependence","volume":"168","author":"Anton","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1111\/acer.12197-BIB0008|acer12197-cit-0008","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"key":"10.1111\/acer.12197-BIB0009|acer12197-cit-0009","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/j.1742-1241.2009.02168.x","article-title":"Understanding heterogeneity in meta-analysis: the role of meta-regression","volume":"63","author":"Baker","year":"2009","journal-title":"Int J Clin Pract"},{"key":"10.1111\/acer.12197-BIB0010|acer12197-cit-0010","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1097\/01.ALC.0000075548.83053.A9","article-title":"A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence","volume":"27","author":"Balldin","year":"2003","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1111\/acer.12197-BIB0011|acer12197-cit-0011","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1111\/j.1360-0443.2008.02355.x","article-title":"Comparing topiramate with naltrexone in the treatment of alcohol dependence","volume":"103","author":"Baltieri","year":"2008","journal-title":"Addiction"},{"key":"10.1111\/acer.12197-BIB0012|acer12197-cit-0012","doi-asserted-by":"crossref","first-page":"136","DOI":"10.15288\/jsa.2004.65.136","article-title":"Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting","volume":"65","author":"Baltieri","year":"2004","journal-title":"J Stud Alcohol"},{"key":"10.1111\/acer.12197-BIB0013|acer12197-cit-0013","first-page":"149","article-title":"Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study","volume":"18","author":"Barrias","year":"1997","journal-title":"Psiquiatria Clinica"},{"key":"10.1111\/acer.12197-BIB0014|acer12197-cit-0014","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1530-0277.1998.tb04295.x","article-title":"Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study","volume":"22","author":"Besson","year":"1998","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1111\/acer.12197-BIB0015|acer12197-cit-0015","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1176\/appi.ajp.2008.08020247","article-title":"Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder","volume":"166","author":"Bridge","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1111\/acer.12197-BIB0016|acer12197-cit-0016","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/alcalc\/35.6.587","article-title":"A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse","volume":"35","author":"Chick","year":"2000a","journal-title":"Alcohol Alcohol"},{"key":"10.1111\/acer.12197-BIB0017|acer12197-cit-0017","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/alcalc\/35.2.176","article-title":"United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol","volume":"35","author":"Chick","year":"2000b","journal-title":"Alcohol Alcohol"},{"key":"10.1111\/acer.12197-BIB0018|acer12197-cit-0018","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/acer.12067","article-title":"The declining efficacy of naltrexone pharmacotherapy for alcohol use disorders over time: a multivariate meta-analysis","volume":"37","author":"Del Re","year":"2013","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1111\/acer.12197-BIB0019|acer12197-cit-0019","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00004714-200112000-00004","article-title":"The double-blind variable placebo lead-in period: results from two antidepressant clinical trials","volume":"21","author":"Faries","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/acer.12197-BIB0020|acer12197-cit-0020","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1159\/000069738","article-title":"The problem of the placebo response in clinical trials for psychiatric disorders: culprits, possible remedies, and a novel study design approach","volume":"72","author":"Fava","year":"2003","journal-title":"Psychother Psychosom"},{"key":"10.1111\/acer.12197-BIB0021|acer12197-cit-0021","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/01.ALC.0000171061.03686.BC","article-title":"Does effect size in naltrexone trials for alcohol dependence differ for single-site vs multi-center studies?","volume":"29","author":"Feinn","year":"2005","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1111\/acer.12197-BIB0022|acer12197-cit-0022","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/j.1530-0277.2011.01716.x","article-title":"A double-blind, placebo-controlled trial assessing the effiacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients","volume":"36","author":"Fertig","year":"2012","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1111\/acer.12197-BIB0023|acer12197-cit-0023","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0140-6736(09)61706-2","article-title":"Biological, clinical, and ethical advances of placebo effects","volume":"375","author":"Finniss","year":"2010","journal-title":"Lancet"},{"key":"10.1111\/acer.12197-BIB0024|acer12197-cit-0024","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/00004714-200212000-00009","article-title":"Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study","volume":"22","author":"Gastpar","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/acer.12197-BIB0025|acer12197-cit-0025","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000259166","article-title":"Acamprosate and prevention of relapse in alcoholics. Results of a randomised, placebo-controlled, double-blind study in out-patient alcoholics in the Netherlands, Belgium and Luxembourg","volume":"3","author":"Geerlings","year":"1997","journal-title":"Eur Addict Res"},{"key":"10.1111\/acer.12197-BIB0026|acer12197-cit-0026","unstructured":"de Goes e Castro LA 2004 Randomized, double-blind clinical trial with naltrexone and brief therapy for the in-patient treatment of alcohol dependence [Ensaio Clinico duplo-cego randomizado e placebo-controlado com naltrexona associado a intervencao breve no treatmento ambulatorial da dependencia alcohol] Federal University of Sao Paulo"},{"key":"10.1111\/acer.12197-BIB0027|acer12197-cit-0027","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/alcalc\/36.5.413","article-title":"Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain","volume":"36","author":"Gual","year":"2001","journal-title":"Alcohol Alcohol"},{"key":"10.1111\/acer.12197-BIB0028|acer12197-cit-0028","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1111\/j.1530-0277.2002.tb02682.x","article-title":"A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial","volume":"26","author":"Guardia","year":"2002","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1111\/acer.12197-BIB0029|acer12197-cit-0029","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1097\/01.ALC.0000139823.30096.52","article-title":"A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence","volume":"28","author":"Johnson","year":"2004","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1111\/acer.12197-BIB0030|acer12197-cit-0030","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/bmj.39524.439618.25","article-title":"Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome","volume":"336","author":"Kaptchuk","year":"2008","journal-title":"BMJ"},{"key":"10.1111\/acer.12197-BIB0031|acer12197-cit-0031","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/schbul\/sbn110","article-title":"What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?","volume":"36","author":"Kemp","year":"2010","journal-title":"Schizophr Bull"},{"key":"10.1111\/acer.12197-BIB0032|acer12197-cit-0032","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.NMD.0000061144.16176.38","article-title":"Placebo response and antidepressant clinical trial outcome","volume":"191","author":"Khan","year":"2003","journal-title":"J Nerv Ment Dis"},{"key":"10.1111\/acer.12197-BIB0033|acer12197-cit-0033","first-page":"464","article-title":"Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications","volume":"72","author":"Khin","year":"2011","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/acer.12197-BIB0034|acer12197-cit-0034","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archpsyc.60.1.92","article-title":"Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study","volume":"60","author":"Kiefer","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/acer.12197-BIB0035|acer12197-cit-0035","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1371\/journal.pmed.0050045","article-title":"Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration","volume":"5","author":"Kirsch","year":"2008","journal-title":"PLoS Med"},{"key":"10.1111\/acer.12197-BIB0036|acer12197-cit-0036","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/JCP.0b013e3181d20912","article-title":"Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response","volume":"30","author":"Kobak","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/acer.12197-BIB0037|acer12197-cit-0037","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/10550490701756120","article-title":"Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials","volume":"17","author":"Kranzler","year":"2008","journal-title":"Am J Addict"},{"key":"10.1111\/acer.12197-BIB0038|acer12197-cit-0038","first-page":"1074","article-title":"Sustained-release naltrexone for alcoholism treatment: a preliminary study","volume":"22","author":"Kranzler","year":"1998","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1111\/acer.12197-BIB0039|acer12197-cit-0039","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0893-133X(99)00135-9","article-title":"Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial","volume":"22","author":"Kranzler","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1111\/acer.12197-BIB0040|acer12197-cit-0040","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/j.1530-0277.2001.tb02356.x","article-title":"Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis","volume":"25","author":"Kranzler","year":"2001","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1111\/acer.12197-BIB0041|acer12197-cit-0041","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/01.ALC.0000130804.08397.29","article-title":"Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial","volume":"28","author":"Kranzler","year":"2004","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1111\/acer.12197-BIB0042|acer12197-cit-0042","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1056\/NEJMoa011127","article-title":"Naltrexone in the treatment of alcohol dependence","volume":"345","author":"Krystal","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/acer.12197-BIB0043|acer12197-cit-0043","first-page":"182","article-title":"Acamprosate-a stabilizing factor in long-term withdrawal of alcoholic patients","volume":"50","author":"Ladewig","year":"1993","journal-title":"Ther Umsch"},{"key":"10.1111\/acer.12197-BIB0044|acer12197-cit-0044","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/pst.267","article-title":"Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches","volume":"7","author":"Lane","year":"2008","journal-title":"Pharm Stat"},{"key":"10.1111\/acer.12197-BIB0045|acer12197-cit-0045","doi-asserted-by":"crossref","first-page":"530","DOI":"10.5694\/j.1326-5377.2002.tb04550.x","article-title":"Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting","volume":"176","author":"Latt","year":"2002","journal-title":"Med J Aust"},{"key":"10.1111\/acer.12197-BIB0047|acer12197-cit-0047","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1080\/09595230120058579","article-title":"Naltrexone in the treatment of male alcoholics-an effectiveness study in Singapore","volume":"20","author":"Lee","year":"2001","journal-title":"Drug Alcohol Rev"},{"key":"10.1111\/acer.12197-BIB0046|acer12197-cit-0046","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1471-2288-9-55","article-title":"A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder","volume":"9","author":"Lee","year":"2009","journal-title":"BMC Med Res Methodol"},{"key":"10.1111\/acer.12197-BIB0048|acer12197-cit-0048","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0140-6736(85)91615-0","article-title":"Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics","volume":"1","author":"Lhuintre","year":"1985","journal-title":"Lancet"},{"key":"10.1111\/acer.12197-BIB0049|acer12197-cit-0049","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/oxfordjournals.alcalc.a045057","article-title":"Acamprosate appears to decrease alcohol intake in weaned alcoholics","volume":"25","author":"Lhuintre","year":"1990","journal-title":"Alcohol Alcohol"},{"key":"10.1111\/acer.12197-BIB0050|acer12197-cit-0050","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archgenpsychiatry.2010.88","article-title":"Effects of expectation on placebo-induced dopamine release in Parkinson disease","volume":"67","author":"Lidstone","year":"2010","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/acer.12197-BIB0051|acer12197-cit-0051","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1530-0277.2011.01649.x","article-title":"A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients","volume":"36","author":"Litten","year":"2012","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1111\/acer.12197-BIB0052|acer12197-cit-0052","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"},{"key":"10.1111\/acer.12197-BIB0053|acer12197-cit-0053","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jpsychires.2011.03.001","article-title":"Recent developments in improving signal detection and reducing placebo response in psychiatric clinical trials","volume":"45","author":"Mallinckrodt","year":"2011","journal-title":"J Psychiatr Res"},{"key":"10.1111\/acer.12197-BIB0054|acer12197-cit-0054","first-page":"53","article-title":"Signal detection and placebo response in schizophrenia: parallels with depression","volume":"43","author":"Mallinckrodt","year":"2010","journal-title":"Psychopharmacol Bull"},{"key":"10.1111\/acer.12197-BIB0055|acer12197-cit-0055","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/01.ALC.0000108656.81563.05","article-title":"The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis","volume":"28","author":"Mann","year":"2004","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1111\/acer.12197-BIB0056|acer12197-cit-0056","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1530-0277.2011.01616.x","article-title":"Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data","volume":"36","author":"Mason","year":"2012","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1111\/acer.12197-BIB0057|acer12197-cit-0057","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/clpt.2010.159","article-title":"A new population-enrichment strategy to improve efficiency of placebo-controlled clinical trials of antidepressant drugs","volume":"88","author":"Merlo-Pich","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1111\/acer.12197-BIB0058|acer12197-cit-0058","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/j.1530-0277.2001.tb02170.x","article-title":"Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes","volume":"25","author":"Monti","year":"2001","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1111\/acer.12197-BIB0059|acer12197-cit-0059","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1111\/j.1360-0443.2006.01555.x","article-title":"Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial","volume":"101","author":"Morley","year":"2006","journal-title":"Addiction"},{"key":"10.1111\/acer.12197-BIB0060|acer12197-cit-0060","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1046\/j.1360-0443.2001.961115654.x","article-title":"Naltrexone for alcohol dependence: a randomized controlled trial","volume":"96","author":"Morris","year":"2001","journal-title":"Addiction"},{"key":"10.1111\/acer.12197-BIB0061|acer12197-cit-0061","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.291.15.1887","article-title":"Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis","volume":"291","author":"Nunes","year":"2004","journal-title":"JAMA"},{"key":"10.1111\/acer.12197-BIB0062|acer12197-cit-0062","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","article-title":"Naltrexone and coping skills therapy for alcohol dependence. A controlled study","volume":"49","author":"O'Malley","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/acer.12197-BIB0063|acer12197-cit-0063","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1111\/j.1530-0277.2008.00682.x","article-title":"Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial","volume":"32","author":"O'Malley","year":"2008","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1111\/acer.12197-BIB0064|acer12197-cit-0064","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1530-0277.2007.00347.x","article-title":"Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial","volume":"31","author":"O'Malley","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1111\/acer.12197-BIB0066|acer12197-cit-0066","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00019442-199700540-00007","article-title":"Naltrexone as an adjunctive treatment for older patients with alcohol dependence","volume":"5","author":"Oslin","year":"1997","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1111\/acer.12197-BIB0065|acer12197-cit-0065","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00019442-200506000-00008","article-title":"Treatment of late-life depression complicated by alcohol dependence","volume":"13","author":"Oslin","year":"2005","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1111\/acer.12197-BIB0067|acer12197-cit-0067","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1530-0277.2008.00698.x","article-title":"A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention","volume":"32","author":"Oslin","year":"2008","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1111\/acer.12197-BIB0068|acer12197-cit-0068","first-page":"239","article-title":"Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol","volume":"30","author":"Paille","year":"1995","journal-title":"Alcohol Alcohol"},{"key":"10.1111\/acer.12197-BIB0069|acer12197-cit-0069","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.euroneuro.2008.08.009","article-title":"Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD","volume":"19","author":"Papakostas","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1111\/acer.12197-BIB0070|acer12197-cit-0070","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/978-1-4612-2878-3_44","volume-title":"Novel Pharmacological Interventions for Alcoholism","author":"Pelc","year":"1992"},{"key":"10.1111\/acer.12197-BIB0071|acer12197-cit-0071","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1192\/bjp.171.1.73","article-title":"Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study","volume":"171","author":"Pelc","year":"1997","journal-title":"Br J Psychiatry"},{"key":"10.1111\/acer.12197-BIB0072|acer12197-cit-0072","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00213-003-1658-9","article-title":"Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia","volume":"172","author":"Petrakis","year":"2004","journal-title":"Psychopharmacology"},{"key":"10.1111\/acer.12197-BIB0073|acer12197-cit-0073","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1016\/j.biopsych.2005.02.016","article-title":"Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders","volume":"57","author":"Petrakis","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1111\/acer.12197-BIB0074|acer12197-cit-0074","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jsat.2007.05.011","article-title":"Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence","volume":"34","author":"Pettinati","year":"2008","journal-title":"J Subst Abuse Treat"},{"key":"10.1111\/acer.12197-BIB0075|acer12197-cit-0075","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1176\/appi.ajp.2009.08060852","article-title":"A double-blind, placebo-controlled trial combining sertraline and naltrexone for treating co-occurring depression and alcohol dependence","volume":"167","author":"Pettinati","year":"2010","journal-title":"Am J Psychiatry"},{"key":"10.1111\/acer.12197-BIB0076|acer12197-cit-0076","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1111\/j.1360-0443.1997.tb02873.x","article-title":"Acamprosate treatment in a long-term community-based alcohol rehabilitation programme","volume":"92","author":"Poldrugo","year":"1997","journal-title":"Addiction"},{"key":"10.1111\/acer.12197-BIB0077|acer12197-cit-0077","first-page":"CD004332","article-title":"Acamprosate for alcohol dependence","volume":"9","author":"R\u00f6sner","year":"2010a","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/acer.12197-BIB0078|acer12197-cit-0078","first-page":"CD001867","article-title":"Opioid antagonists for alcohol dependence","volume":"12","author":"R\u00f6sner","year":"2010b","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1111\/acer.12197-BIB0079|acer12197-cit-0079","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1001\/archpsyc.1996.01830080023006","article-title":"Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence","volume":"53","author":"Sass","year":"1996","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/acer.12197-BIB0080|acer12197-cit-0080","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1176\/ajp.127.12.1653","article-title":"The Michigan alcoholism screening test: the quest for a new diagnostic instrument","volume":"127","author":"Selzer","year":"1971","journal-title":"Am J Psychiatry"},{"key":"10.1111\/acer.12197-BIB0081|acer12197-cit-0081","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/10543401003777995","article-title":"MMRM versus MI in dealing with missing data-a comparison based on 25 NDA data sets","volume":"21","author":"Siddiqui","year":"2011","journal-title":"J Biopharm Stat"},{"key":"10.1111\/acer.12197-BIB0082|acer12197-cit-0082","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/10543400802609797","article-title":"MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets","volume":"19","author":"Siddiqui","year":"2009","journal-title":"J Biopharm Stat"},{"key":"10.1111\/acer.12197-BIB0083|acer12197-cit-0083","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4088\/JCP.08r04516blu","article-title":"Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses","volume":"71","author":"Sinyor","year":"2010","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/acer.12197-BIB0084|acer12197-cit-0084","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1037\/0021-843X.91.3.199","article-title":"Alcohol dependence syndrome: measurement and validation","volume":"91","author":"Skinner","year":"1982","journal-title":"J Abnorm Psychol"},{"key":"10.1111\/acer.12197-BIB0085|acer12197-cit-0085","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1017\/S1461145704004997","article-title":"Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials","volume":"8","author":"Srisurapanont","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1111\/acer.12197-BIB0086|acer12197-cit-0086","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/alcalc\/36.6.544","article-title":"Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials","volume":"36","author":"Streeton","year":"2001","journal-title":"Alcohol Alcohol"},{"key":"10.1111\/acer.12197-BIB0087|acer12197-cit-0087","unstructured":"Sutton AJ Abrams KR Jones DR Sheldon TA Song F 2000 Methods for Meta-Analysis in Medical Research John Wiley & Sons, Ltd West Sussex, UK"},{"key":"10.1111\/acer.12197-BIB0088|acer12197-cit-0088","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/alcalc\/35.2.202","article-title":"Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study","volume":"35","author":"Tempesta","year":"2000","journal-title":"Alcohol Alcohol"},{"key":"10.1111\/acer.12197-BIB0089|acer12197-cit-0089","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"Thompson","year":"2002","journal-title":"Stat Med"},{"key":"10.1111\/acer.12197-BIB0090|acer12197-cit-0090","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/npp.2011.306","article-title":"Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review","volume":"37","author":"Undurraga","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1111\/acer.12197-BIB0091|acer12197-cit-0091","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/archpsyc.1992.01820110040006","article-title":"Naltrexone in the treatment of alcohol dependence","volume":"49","author":"Volpicelli","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/acer.12197-BIB0092|acer12197-cit-0092","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archpsyc.1997.01830200071010","article-title":"Naltrexone and alcohol dependence. Role of subject compliance","volume":"54","author":"Volpicelli","year":"1997","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/acer.12197-BIB0093|acer12197-cit-0093","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1001\/jama.287.14.1840","article-title":"Placebo response in studies of major depression: variable, substantial, and growing","volume":"287","author":"Walsh","year":"2002","journal-title":"JAMA"},{"key":"10.1111\/acer.12197-BIB0094|acer12197-cit-0094","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1097\/01.jcp.0000162810.76947.bf","article-title":"Placebo control groups in trials of major depressive disorder among older patients","volume":"25","author":"Walsh","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"10.1111\/acer.12197-BIB0095|acer12197-cit-0095","doi-asserted-by":"crossref","first-page":"878","DOI":"10.15288\/jsad.2008.69.878","article-title":"Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study","volume":"69","author":"Weiss","year":"2008","journal-title":"J Stud Alcohol Drugs"},{"key":"10.1111\/acer.12197-BIB0096|acer12197-cit-0096","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0140-6736(96)91682-7","article-title":"Comparison of acamprosate and placebo in long-term treatment of alcohol dependence","volume":"347","author":"Whitworth","year":"1996","journal-title":"Lancet"},{"key":"10.1111\/acer.12197-BIB0097|acer12197-cit-0097","unstructured":"Wilson DB 2010 Meta-analysis macros for SAS, SPSS, and Stata http:\/\/mason.gmu.edu\/~dwilsonb\/ma.html"},{"key":"10.1111\/acer.12197-BIB0098|acer12197-cit-0098","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.drugalcdep.2011.05.001","article-title":"The effects of combined acamprosate and integrative behaviour therapy in the outpatient treatment of alcohol dependence: a randomized controlled trial","volume":"118","author":"W\u00f6lwer","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"10.1111\/acer.12197-BIB0099|acer12197-cit-0099","unstructured":"World Health Organization 1992 The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines World Health Organization Geneva, Switzerland"}],"container-title":["Alcoholism: Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Facer.12197","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/acer.12197\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T08:44:21Z","timestamp":1715762661000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/acer.12197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,24]]},"references-count":99,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"URL":"https:\/\/doi.org\/10.1111\/acer.12197","relation":{},"ISSN":["0145-6008"],"issn-type":[{"value":"0145-6008","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7,24]]}}}